Meet The Team
Chairman
Chief Executive Officer
Chief Executive Officer
Carlton M. Cadwell
Dr. Carlton Cadwell leverages over 30 years of experience in the corporate world leading Cadwell Laboratories, a major international provider of neurodiagnostic devices. Dr. Carlton Cadwell brings a proven track record in business leadership and innovation.
Chief Executive Officer
Chief Executive Officer
Chief Executive Officer
Dr. Michael Korenko
Dr. Michael Korenko has advanced degrees from Case-Western Reserve University and MIT and was a NATO Postdoctoral Fellow at Oxford University. He served as a White House Fellow at the Department of Defense and the Office of Science and Technology. He has had several publications, 30 patents, and was awarded the Quality Manager of the year by Westinghouse Corporation, the first ever award to a manager from the US Steelworkers for excellence in promoting safety, the National Energy Resources Organization Research and Development Award, and a Friend of the Nez Pierce Nation Nez Perce Tribal Award for forming the Native American Program. He has been a successful senior manager at Westinghouse and Curtiss Wright Corporation. He has extensive experience in nuclear materials and manufacturing. As CEO he has transformed Vivos Inc from financial jeopardy into a streamlined organization focusing on Precision Radio Nuclide Therapy for animals and humans.
President
Chief Executive Officer
Chief Operating Officer
Brad Weeks
Mr. Brad Weeks is a seasoned leader with extensive experience in the medical device and biotechnology sectors. As President, Brad plays a pivotal role in business development, team expansion, and strategic partnerships, contributing to the Company’s growth in targeted cancer therapies that deliver radioactive agents directly to tumors while minimizing damage to healthy tissue. Brad has built a distinguished career in healthcare innovation, holding leadership positions at organizations focused on advancing medical technologies and patient outcomes. His expertise includes forging international collaborations, such as recent engagements in India. Passionate about groundbreaking solutions that improve lives, Brad is actively involved in promoting the Company’s mission to revolutionize oncology through safer, more effective radionuclide therapies. Mr. Weeks holds a Master of Business Administration (MBA) with a focus on Technology Management.
Chief Operating Officer
Product Development Manager
Chief Operating Officer
David Swanberg
Mr. Swanberg has over 35 years’ experience in Radiochemical Processing, Medical Isotope Production, Nuclear Waste Management, Materials Science, Regulatory Affairs, and Project Management. He has worked in diverse organizations ranging from small start-up businesses to corporations with multi-billion-dollar annual revenues. Most recently, he served as Technology Development Project Manager for Washington River Protection Solutions, from 2010 to 2024. Prior to 2010, she served as Senior Chemical/Environmental Engineer for Science Applications International Corporation since 2008. He has also previously served as Executive Vice President of Operations for IsoRay Medical Inc. managing day-to-day operations, R&D, and New Product Development. Mr. Swanberg was a co-founder of IsoRay and led the initial Cs-131 brachytherapy seed product development, FDA 510(k) submission/clearance, and NRC Sealed Source review and registration. He led the radiation dosimetry evaluations to meet American Association of Physicists in Medicine guidelines and is a current member of the AAPM. Mr. Swanberg served on the IsoRay Board of Directors and participated in several capital financing rounds totaling over $30.0 million. Mr. Swanberg has been actively engaged with the Company in his previous role as Chief Technical Manager since 2017. He has been integrally involved in product development, production, user training, regulatory submissions, and intellectual property development. He holds a BA in Chemistry from Bethel University (MN) and an MS in Chemical Engineering from Montana State University. He has numerous technical publications and holds several patents..
Product Development Manager
Product Development Manager
Product Development Manager
Dr. Jim Duncan
Dr. Duncan is a Doctor of Philosophy, holds a Master of Science in Immunochemistry, a Bachelor of Science in Bacteriology and Chemistry. With more than 30 years experience and countless projects, publications and patents under his belt he has worked for the Department of Defense bringing concepts from the laboratory to production. Dr. Duncan oversees the production of more Peltier Chillers.
Quality Assurance Manager
Product Development Manager
Product Development Manager
Frederick Swindler
Mr. Swindler has a B.S. Biomedical Engineering, a M.B.A and is an ISO 9000 Auditor. With over 50 years in the industry Mr. Swindler offers Vivos extensive expertise in quality assurance and regulatory affairs in the medical device industry with specific emphasis in development and auditing of quality systems and product submissions.
Consultant - International Business Advisor
Consultant - International Business Advisor
Consultant - International Business Advisor
Sandip Bali
We are delighted to announce that Mr. Sandip Bali has joined our organization as a business partner to spearhead our international expansion efforts. With over two decades of expertise in the fields of radiotherapy, radioembolization, and interventional oncology, Mr. Bali has an extensive track record of driving business development across the Middle East, Africa, and Asia. His professional journey includes leadership roles at esteemed organizations such as Nordion Inc., Sirtex Medical, Novoste Corporation, and Telix Pharmaceuticals India.
Mr. Bali brings unparalleled expertise in navigating regulatory landscapes and advancing non-uranium production methodologies within the radioisotope industry. He will play a pivotal role in penetrating new markets, establishing strategic alliances, and enhancing our global presence. His deep understanding of the industry and proven business development acumen align seamlessly with our mission to innovate and achieve sustainable growth in the field of radiopharmaceuticals.
Client Relations Manager
Consultant - International Business Advisor
Consultant - International Business Advisor
LeeAnna D. Binder
LeeAnna supports Vivos, specifically the IsoPet® division with business development, marketing, training, client relations, and clinic engagement. Bringing more than 30 years of experience in sales, customer service, and business development, LeeAnna's background spans multiple industries where she has been involved in building companies from the ground up, giving her a strong foundation in operations, communication, and customer support. Her passion lies with establishing long-term connections in the veterinary oncology community.
Along with a Business Management Diploma from MacEwan University, LeeAnna is also currently completing her doctorate in Integrative Medicine at Quantum University with an focus on cancer.
Operations & Business Strategist
Consultant - International Business Advisor
Operations & Business Strategist
Megan Binder
Megan supports both human and veterinary divisions in the company, streamlining internal systems and supporting company growth initiatives. She holds a Bachelor of Arts from the University of British Columbia and a Master of Arts degree in Clinical Psychology, which has provided her with a thoughtful, human-centered lens that serves as a strong foundation when communicating across teams, clinics, and partners.
Working largely behind the scenes, Megan is dedicated to supporting daily operations with steady efficiency — helping maintain alignment across departments, and contributing to the polished communication standards across technical, quality, and marketing divisions that represent the company’s brand.
Administrator
Administrator
Operations & Business Strategist
Halle Binder
Halle supports Vivos's internal processes, maintaining, organizing, and overseeing accurate documentation across all departments. She is currently completing her undergraduate degree at MacEwan University and has a talent for bringing order to busy workflows, helping the team operate smoothly and efficiently.
Halle’s work also involves assisting at conferences across the United States and being the comforting voice responding to pet inquiries. She brings reliability, structure, and a solutions-oriented attitude to every task.
A Leader In Precision Radionuclide Therapy™
How We Are Changing The Way Cancer Is Treated
Vivos Inc. - The Leader In Precision Radionuclide Therapy™
Vivos Inc.'s strategic endeavors in medical and veterinary oncology are indeed pushing the boundaries of healthcare innovation. Holding nearly 30 patents including Precision Radionuclide Therapy™ and trademark protection for IsoPet®, RadioGel®, Alpha-Gel™, Beta-Gel™ and Gamma-Gel™ just to name a few, Vivos Inc. is securing its place as the leader in radionuclide therapy.
Expansion into Veterinary Care with IsoPet®
Vivos Inc. has been expanding its reach in veterinary medicine with a Yttrium-90-based Precision Radionuclide Therapy™ for treatment used for solid tumors in animals. The equine healthcare market is experiencing significant growth, driven by rising demand in various sectors including racing and sports, along with increased awareness and investment in equine health. In 2023, the global equine healthcare market size was estimated at approximately $1.5 billion and is projected to reach $2.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of approximately 5.6%. North America is a dominant player in this market, largely because of a well-established equine industry.In terms of veterinary oncology, which includes cancer treatment for horses among other animals, the market was valued at $923.5 million in 2023 and is anticipated to grow to $1.7 billion by 2032. This growth is attributed to the increasing incidence of cancer among animals, advancements in cancer diagnostics and treatment, and a greater focus on pet health.
Vivos Inc. has been focusing efforts to certify additional clinics to offer IsoPet® treatment, enhancing access to advanced cancer treatments for cats, dogs and horses. There is also an opportunity to treat exotic animals and the company is in discussion with several interested parties to open a broader market for IsoPet®.
Clinical Trials with RadioGel®
Dr. Michael Korenko, CEO stated, “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel® is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel® for delivering therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease. The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.”
Vivos Inc.'s recent achievement of OTCQB certification is a significant development, underscoring the company's dedication to transparency and regulatory compliance. On March 22, 2024, CEO Dr. Michael Korenko led the company to secure its registration under Section 12(g) of the Exchange Act. This certification is more than procedural; it reflects Vivos Inc.'s strategic foresight and proactive approach in maintaining high governance standards, ultimately benefiting investors and partners by providing clear insights into the company's operations and financial health.
Our team of experts brings together diverse backgrounds and skill sets, enabling us to tackle complex challenges and develop new products that have the potential to change lives. We are committed to making a positive impact on society, and we believe that biotechnology can be a powerful tool for addressing global challenges such as disease, food security, and environmental sustainability.
With critical FDA designations for its groundbreaking treatments and achieving milestones like OTCQB certification, Vivos Inc. is demonstrating its commitment to innovating the treatment of cancer and saving lives worldwide.
Cancer Is On The Rise
At Vivos Inc. we are dedicated to revolutionizing the biotechnology industry. With a focus on innovation and scientific excellence, we are working to find new solutions to the way cancer is treated.
In 2023, it's estimated that around 43,720 recent cases of thyroid cancer will be diagnosed in the United States, with about 2,120 fatalities expected from the disease. Thyroid cancer is notably more prevalent among women than men and tends to be diagnosed at a younger age compared to most other adult cancers, with the average age of diagnosis at 51 years.
The incidence of thyroid cancer has been increasing, which may in part be because of advancements in diagnostic technologies that can now detect smaller cancers that might not have been found in the past. It's important for ongoing research and patient support to adapt to these trends to optimize treatment strategies and improve outcomes.
According to the latest data from the International Agency for Research on Cancer (IARC), there were approximately 20 million new cancer cases and 9.7 million cancer deaths globally in 2022. Lung and breast cancers are the most prevalent worldwide, with lung cancer also being the leading cause of cancer death overall and in men. For women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death.
The projections suggest a surge to 35 million cancer cases by 2050, mainly because of population growth and aging, if current incidence rates remain unchanged.